Candriam S.C.A. Rocket Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $15.4 Billion
- Q1 2024
A detailed history of Candriam S.C.A. transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 165,000 shares of RCKT stock, worth $3.55 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
165,000
Previous 110,000
50.0%
Holding current value
$3.55 Million
Previous $3.3 Million
34.86%
% of portfolio
0.03%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding RCKT
# of Institutions
205Shares Held
92.9MCall Options Held
341KPut Options Held
107K-
Rtw Investments, LP New York, NY17.7MShares$381 Million7.65% of portfolio
-
Wellington Management Group LLP Boston, MA9.16MShares$197 Million0.04% of portfolio
-
Black Rock Inc. New York, NY5.93MShares$128 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.37MShares$116 Million0.0% of portfolio
-
State Street Corp Boston, MA4.19MShares$90.3 Million0.01% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $1.63B
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...